CD163 and breast carcinoma: In a cohort of 40 HER2+ breast cancer patients who received trastuzumab, an anti-HER2 therapy, a high number of M1-like macrophages (iNOS+) were significantly associated with improved survival whereas high expression of M2-like macrophages (CD163+) were associated with worse prognosis (144).